Is This Atrial Fibrillation Drug Done For After FDA Vote?

Posted: December 11, 2019 at 12:20 pm

Correvio Pharma Corp. (NASDAQ: CORV) shares were crushed after the firm announced the U.S. Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) decision for its New ...
Read Full Story »

Why This Cystic Fibrosis Study Is Getting a Big Boost

Posted: December 11, 2019 at 11:10 am

Proteostasis Therapeutics Inc. (NASDAQ: PTI) shares jumped on Wednesday after the firm announced positive, initial ex-vivo results of its proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808 and ...
Read Full Story »

Major Biotechs See a Rising Tide in Short Interest

Posted: December 11, 2019 at 9:10 am

The short interest data are out for the most recent settlement date, November 29. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big ...
Read Full Story »

Will This FDA Decision Set Off These Late-Stage Dermatitis Studies?

Posted: December 10, 2019 at 10:10 am

Dermira Inc. (NASDAQ: DERM) shares jumped on Tuesday after the firm announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for lebrikizumab, its treatment being ...
Read Full Story »

Why Fate Therapeutics Is One of ASH’s Biggest Winners

Posted: December 9, 2019 at 11:50 am

Fate Therapeutics Inc. (NASDAQ: FATE) shares jumped on Monday after the firm announced new preclinical data for its off-the-shelf, multi-antigen targeting natural killer cell product candidate derived from a clonal ...
Read Full Story »

Why These 3 Biotechs More Than Doubled on Monday

Posted: December 9, 2019 at 10:40 am

Monday was a breakout day for a few biotech companies. Some made absolutely massive runs, practically doubling and then some. The biotechnology sector is pushing near all-time highs, and a ...
Read Full Story »

Is the Sage Therapeutics Implosion Overblown?

Posted: December 6, 2019 at 11:25 am

Sage Therapeutics Inc. (NASDAQ: SAGE) shareholders took a bath on Thursday after results from its late-stage major depressive disorder (MDD) trial came public. Despite shares getting more than halved in ...
Read Full Story »

Thursday’s Biggest Biotech Movers

Posted: December 5, 2019 at 11:20 am

Thursday was a breakout day for a few biotech companies. Some made absolutely massive runs, while others fell off a cliff. The biotechnology sector is pushing near all-time highs, and ...
Read Full Story »

Why This Transfusion-Dependent Beta-Thalassemia Trial Is Taking Off

Posted: December 4, 2019 at 12:00 pm

Protagonist Therapeutics Inc. (NASDAQ: PTGX) shares jumped on Wednesday after the company announced preliminary results from its midstage study for patients with transfusion-dependent beta-thalassemia. Specifically, the results come from the ...
Read Full Story »

biotech